The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial

Trial Profile

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs JNJ 39393406 (Primary)
  • Indications Bipolar depression; Depressive disorders
  • Focus Therapeutic Use
  • Acronyms JNJ-DEP
  • Most Recent Events

    • 28 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
    • 28 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.
    • 02 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top